Skip to main content
. 2021 Apr 29;11(4):84. doi: 10.1038/s41408-021-00469-5

Fig. 5. CD19-antigen decoy for innovative targeting of myeloma cells.

Fig. 5

Increased expression of CD19 is induced on the myeloma cells by artificially creating the protein-anti-BCMA antibody complex that binds to endogenous surface BCMA. Highly potent and specific anti-CD19 CAR-T can be used to target these synthetic myeloma cells.